The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment

被引：0
|
作者：
Allen, Frederick [1 ,2 ]
Dorand, Rodney Dixon [1 ]
Rauhe, Peter [1 ,2 ]
Petrosiute, Agne [1 ,2 ,3 ]
Huang, Alex Y. [2 ,4 ,5 ]
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Univ Hosp, Dept Pediat, Cleveland, OH USA
[3] Rainbow Babies & Childrens Hosp, Univ Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA
[4] Angie Fowler AYA Canc Inst, Cleveland, OH USA
[5] Case Comprehens Canc, Cleveland, OH USA
来源：
JOURNAL OF IMMUNOLOGY | 2018年 / 200卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
178.14
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PD-L1 blockade efficacy relies on host cell PD-L1
    Brownell, I.
    Udey, M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : 1000 - 1000
  • [2] Relevance of host and tumor PD-L1 in PD-L1 pathway blockade
    Kryczek, Ilona
    Lin, Heng
    Wei, Shuang
    Green, Michael
    Zou, Weiping
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [3] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    [J]. JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [4] Mild hyperthermia upregulates PD-L1 in the tumor microenvironment and enhances antitumor efficacy of PD-L1 blockade in murine squamous cell carcinoma
    Ohta, Yuya
    Ichimura, Norihisa
    Yamaguchi, Satoshi
    Ohara, Go
    Yamamoto, Noriyuki
    Itoh, Yoshiyuki
    Yamada, Keiichiro
    Nakamura, Seiji
    Hibi, Hideharu
    [J]. NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (03): : 497 - 506
  • [5] Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
    Lin, Heng
    Wei, Shuang
    Hurt, Elaine M.
    Green, Michael D.
    Zhao, Lili
    Vatan, Linda
    Szeliga, Wojciech
    Herbst, Ronald
    Harms, Paul W.
    Fecher, Leslie A.
    Vats, Pankaj
    Chinnaiyan, Arul M.
    Lao, Christopher D.
    Lawrence, Theodore S.
    Wicha, Max
    Hamanishi, Junzo
    Mandai, Masaki
    Kryczek, Ilona
    Zou, Weiping
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (02): : 805 - 815
  • [6] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
    Gumuzio, Juan
    Calleja, Veronique
    Miles, James
    Sancehz-Magraner, Lissete
    Aguirre, Fernando
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [7] PD-L1 expression of medulloblastoma
    Cakmak, P.
    Kolay, E.
    Poyraz, A.
    [J]. VIRCHOWS ARCHIV, 2018, 473 : S28 - S28
  • [8] Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
    Mengling Wu
    Qianrui Huang
    Yao Xie
    Xuyi Wu
    Hongbo Ma
    Yiwen Zhang
    Yong Xia
    [J]. Journal of Hematology & Oncology, 15
  • [9] PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
    Tang, Haidong
    Liang, Yong
    Anders, Robert A.
    Taube, Janis M.
    Qiu, Xiangyan
    Mulgaonkar, Aditi
    Liu, Xin
    Harrington, Susan M.
    Guo, Jingya
    Xin, Yangchun
    Xiong, Yahong
    Nham, Kien
    Silvers, William
    Hao, Guiyang
    Sun, Xiankai
    Chen, Mingyi
    Hannan, Raquibul
    Qiao, Jian
    Dong, Haidong
    Peng, Hua
    Fu, Yang-Xin
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (02): : 580 - 588
  • [10] Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
    Wu, Mengling
    Huang, Qianrui
    Xie, Yao
    Wu, Xuyi
    Ma, Hongbo
    Zhang, Yiwen
    Xia, Yong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
12345